70
Participants
Start Date
August 23, 2021
Primary Completion Date
March 21, 2022
Study Completion Date
July 18, 2022
Tezepelumab
210 mg SC injection Q4W.
Placebo
SC injection Q4W.
Research Site, Miami
Research Site, Toledo
Research Site, Dayton
Research Site, Milwaukee
Research Site, Columbia
Research Site, Edmond
Research Site, Oklahoma City
Research Site, Dallas
Research Site, Tyler
Research Site, Waco
Research Site, San Antonio
Research Site, Salt Lake City
Research Site, Huntington Beach
Research Site, Bakersfield
Research Site, Northfield
Lead Sponsor
Collaborators (1)
Amgen
INDUSTRY
AstraZeneca
INDUSTRY